Compare ARK Genomic Revolution ETF (ARKG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs GeneDx Holdings Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while GeneDx Holdings Corp trades at $64.93 (market cap $1.95B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $167.51 |
52-Week Low | $23.09 | $34.51 |
Market Cap | — | $1.95B |
Enterprise Value | — | $1.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
GeneDx Holdings (WGS) trades at $65.64, down 5.4% over 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $427.54 million in 2025 but a net loss of $21.02 million, with profitability metrics like ROE at -30.42% indicating financial strain. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading statements related to the Fabric Genomics acquisition.
While analyst consensus remains strongly bullish with a $75.40 price target, the stock faces significant risks from ongoing litigation and persistent losses. Investment appeal hinges on the company's ability to improve margins and navigate legal challenges, but current fundamentals suggest caution despite optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
